33 results about "Toxin Conjugates" patented technology

The present invention relates to compositions and methods for inducing cell death or stasis in cancer cells or other hyperproliferative cells using anti-EphA2 or anti-EphA4 antibodies conjugated to toxins.

Methods are described for improvement of the serum half life of therapeutic nucleic acids by 3′ conjugation to useful target proteins, or other large molecules with useful function. In one embodiment, a 3′ A, C or G overhang is added to ds-DNA and the primary amines conjugated using biocompatible bifunctional linkers to proteins. The resulting nucleic acid-3′-conjugates are serum nuclease-resistant and retained in vivo for long periods without rapid kidney clearance. Further, the choice of conjugate imparts additional functionality to the nucleic acid-3-conjugate. For example, if the protein in the DNA-protein conjugate is the first component of the complement cascade (Clq or Clqrs) and the DNA aptamer has been developed against surface components of a target cell, it can be used to treat bacterial or parasitic infections and cancers. If the protein is serum albumin or another common (nonimmunogenic) blood protein and the aptamer is directed against a toxin or venom, the aptamer-protein conjugate can be used as an antidote that binds and neutralizes the toxin or venom. Similar DNA (aptamer)-nanotube, -enzyme, and -toxin conjugates could also be used to target and selectively kill bacteria, parasites, and cancer cells in vivo. If the protein is an Fc antibody fragment or C3b protein from the complement system and the aptamer is developed against a bacterial cell capsular material, other cell surface component or viral cell surface component, then the aptamer-3′-protein conjugate can aid in opsonization of the target cells or viruses by phagocytic leukocytes.

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of a toxin and a target-binding moiety, e.g. an antibody, which are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moiety is preferably directed against tumour-associated antigens. In particular, the amatoxin is conjugated to the antibody by linker moieties. In particular the linker moieties are covalently bound to functional groups located in positions of the amatoxin proved as preferred positions for the attachment of linkers with respect to optimum antitumor activity. In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer.

Compositions and methods for treatment of focal muscle spasms. Immunotoxin conjugates comprise a toxin conjugated to an antibody reactive to a muscle specific antigen.

This invention generally relates to a method of identifying pre-neoplastic or neoplastic tissue of a mammal by utilizing autoantibodies that detect the pre-neoplastic or neoplastic tissue. Also described herein are methods of killing pre-neoplastic or neoplastic tissue by either binding toxins to autoantibodies that detect the pre-neoplastic or neoplastic tissue or introducing toxin-conjugated molecules that can in turn recognize the autoantibodies already bound to the pre-neoplastic or neoplastic tissue.

The present invention provides an enzyme linked immunoassay kit for detecting T-2 toxin. The kit contains a T-2 toxin conjugated antigen coated enzyme label plate, a T-2 toxin standard substance solution, a concentrated enzyme conjugate, an enzyme conjugate working solution, a substrate coloration solution and a termination solution. The invention further discloses a method for detecting T-2 toxin in a sample by using the enzyme linked immunoassay kit. The method comprises: carrying out a sample pretreatment, detecting by using the kit, and analyzing the detection result. The enzyme linked immunoassay kit can be used for detecting T-2 toxin residue in feed (raw materials, matching materials and concentrated materials) samples, has characteristics of simple operation, low cost, high sensitivity and on-site monitoring, and is suitable for screening of mass samples.

The present invention relates to drug conjugates comprising bicyclic peptides specific for MT1-MMP conjugated to one or more effector and/or functional groups which have utility in targeted cancer therapy.

The invention relates to tumour therapy. In one aspect, the present invention relates to conjugates of target-binding moieties and toxins that are useful in the treatment of cancer. In particular, the toxin is an amatoxin, and the target-binding moieties (e.g. antibodies) are directed against tumour-associated antigens, such as epithelial cell adhesion molecule (EpCAM). In a further aspect the invention relates to pharmaceutical compositions comprising such target-binding moiety toxin conjugates and to the use of such target-binding moiety toxin conjugates for the preparation of such pharmaceutical compositions. The target-binding moiety toxin conjugates and pharmaceutical compositions of the invention are useful for the treatment of cancer, in particular adenocarcinoma, such as pancreatic cancer, cholangiocarcinoma, breast cancer, and colorectal cancer.

The invention discloses a monoclonal antibody-antigen binding segment-T-2 toxin conjugate which is formed by connecting a monoclonal antibody-antigen binding segment with T-2 toxin by using one of a peptide chain, 1,4-butanediol diglycidyl ether, N-hydroxy succinimido-3-(2-pyrazolyl dithio)-propionate as a cross-linking agent. The invention further provides a preparation method of the monoclonal antibody-antigen binding segment-T-2 toxin conjugate and application of the monoclonal antibody-antigen binding segment-T-2 toxin conjugate in preparation of a targeted anti-tumor drug. According to the experiments, the conjugate disclosed by the invention has an obvious targeting performance for tumor tissues, and can be used for lowering the toxicity of the T-2 toxin and improving the inhibiting effect of the conjugate on the tumors.

The present invention relates to Bicycle toxin conjugates, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof, and uses thereof for preventing or treating a disease, disorder, or condition characterised by overexpression of EphA2 in diseased tissue, such as cancer.

The present invention relates to methods for the preparation of toxin conjugates that are useful in vaccination and other therapies and diagnostics. In particular, methods are provided that involve a [3+2] cycloaddition between a first reactive unsaturated group on a toxin moiety and a second reactive unsaturated group on a bioactive moiety. Also provided are conjugates that are formed through this conjugation method, pharmaceutical compositions comprising these conjugates, and methods of using these pharmaceutical compositions for the treatment or diagnostic of antigen-related conditions, including tumors and infections.

The present invention relates to binding protein-toxin conjugates comprising one or more anthracycline toxin moieties, and the use thereof in immunooncological applications.

The present invention relates to a method for detecting the presence of one or more bacterial toxins, capable of binding to cell membranes, in biological fluid wherein the method comprises: (i) incubating the biological fluid with a plurality of liposomes, wherein the liposomes comprise a lipid capable of binding to said one or more toxins, to provide one or more liposome-toxin conjugate; (ii) incubating said conjugates with at least one type of antibody bound to a label to provide one or more conjugate-antibody complex; wherein each type of antibody in the mixture is specific for one of the bacterial toxins whose presence is to be detected; and (iii) analysing said complexes in order to detect the presence of one or more bacterial toxins capable of binding to cell membranes. Further aspects of the invention relate to a conjugate-antibody complex useful in the methods of the invention and a kit useful for performing the method of the invention.

The present invention relates to an amatoxin-linker construct comprising an amatoxin according to formula (I) wherein: R1 and R2 are each -OH, R3 is NH2, or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R4 is H or a linker which carries a reactive group Y for linking said amatoxin to a target-binding moiety, R5 is absent or =O, wherein R3 and R4 cannot be the same, for use in the manufacture of a binding moiety-toxin conjugate for the treatment of a solid tumor, and a respective binding moiety-toxin conjugate for the treatment of a solid tumor.